Surgery of malignant gliomas: Advances and perspectives

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 624-629

  Carapella, Carmine M ^a   Telera, Stefano ^a   Oppido, Piero A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

extent of surgery; fluorescence; intraoperative imaging; locoregional treatments

Indexed keywords

AMINOLEVULINIC ACID; CARMUSTINE; PLACEBO; TEMOZOLOMIDE; TRABEDERSEN;

CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; FLUORESCENCE; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; GLIOMA; HUMANS;

EID: 80054109350     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834ace58     Document Type: Review

References (46)

1. Tabatabai G, Stupp R, van den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 2010; 120:585-592.
2. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009; 15:6683-6693.
3. Hoover JM, Chang SM, Parney FI. Clinical trials in brain tumor surgery. Neuroimag Clin N Am 2010; 20:409-424.
4. Olson JJ, Fadul CE, Brat DJ, et al. Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 2009; 93:1-23.
5. Mikuni N, Miyamoto S. Surgical treatment for glioma: extent of resection applying functional neurosurgery. Neurol Med Chir (Tokyo) 2010; 50:720-726.
6. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-198. (Pubitemid 32799739)
7. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62:753-766.
8. Stupp R, van den Bent MJ, WellerM, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996. (Pubitemid 40349501)
9. Stupp, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-466.
10. Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011; 153:1211-1218.
11. Sanai N, Polley M, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115:3-8.
12. Ngwenya LB, Chiocca EA. Extent of resection, editorial comment. J Neurosurg 2011; 115:1-2.
13. Chaichana KL, Chaichana KK, Alessandro Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg 2011; 114:587-594.
14. Sloan AE. Surgery for glioblastoma multiforme, editorial comment. J Neurosurg 2011; 114:585-586.
15. Chaichana KL, Halthore AN, Parker SL, et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J Neurosurg 2011; 114:604-612.
16. Oppido PA, Fiorindi A, Benvenuti L, et al. Neuroendoscopic biopsy of ventricular tumors: a multicentric experience. Neurosurg Focus 2011; 30:E2.
17. Young RJ, Brennan N, Fraser JF, Brennan C. Advanced imaging in brain tumor surgery. Neuroimag Clin N Am 2010; 20:311-335.
18. Black PM, Moriarty T, Alexander E 3rd, et al. Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. Neurosurgery 1997; 41:831-845. (Pubitemid 27422110)
19. Hatiboglu MA, Weinberg JS, Suki D, et al. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery 2009; 64:1073-1081.
20. Senft C, Franz K, Ulrich CT, et al. Low field intraoperative MRI-guided surgery of gliomas: a single center experience. Clin Neurol Neurosurg 2010; 112:237-243.
21. Kuhnt D, Ganslandt O, Schlaffer SM, et al. Quantification of glioma removal by intraoperative high-field magnetic resonance imaging-an update. Neurosurgery2011. [Epub ahead of print].
22. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42:518-525.
23. Stummer W, Novotny A, Stepp H, et al. Fluorescence guided resection of glioblastoma multiforme by using 5-aminolevulinic acid induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000; 93:1003-1013. (Pubitemid 32800611)
24. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7:392-401.
25. Stummer W, Tonn JC, Mehdorn HM, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg 2011; 114:613-623.
26. Roberts DW, Valdé s PA, Harris BT, et al. Coregistered fluorescenceenhanced tumor resection of malignant glioma: relationships between Daminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 2011; 114:595-603.
27. Eljamel S. Photodynamic applications in brain tumors: a comprehensive review of the literature. Photodiagnosis Photodynamic Ther 2010; 7:76-85.
28. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345:1008-1012.
29. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemo-therapy with carmustine-loaded polymers for high-grade gliomas: a randomized doubleblind study. Neurosurgery 1997; 41:44-48.
30. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 2003; 5:79-88. (Pubitemid 36422560)
31. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148:269-275. (Pubitemid 43341024)
32. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009; 110:583-588.
33. Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010; 33:441-449.
34. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010; 17:1740-1746.
35. McGirt MJ, Brem H. Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 2010; 17:1729-1731.
36. Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high-grade glioma. Cochrane Database Syst Rev 2011;(3):CD007294.
37. Rainov NG, Gorbatyuk K, Heidecke V. Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 2008; 3:2-9. (Pubitemid 351267022)
38. Vandergrift WA, Patel SJ. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus 2006; 20:E13.
39. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010; 12:871-881.
40. Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol 2010; 6:117-125.
41. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13:132-142.
42. Chamberlain MC. Convection-enhanced delivery of a transforming growth factor-b2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined? Neuro-Oncology 2011; 13:558-562. (letter).
43. Rainov NG, Heidecke V. Clinical development of experimental therapies for malignant glioma. Sultan Qaboos Univ Med J 2011; 11:5-28.
44. van Putten EHP, Dirven CMF, van den Bent MJ, Lamfers MLM. Drug Evaluation: sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncology 2010; 6:1691-1710.
45. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60:166-193.
46. Orive G, Ali OA, Anitua E, et al. Biomaterial-based technologies for brain anticancer therapeutics and imaging. Biochim Biophys Acta 2010; 806:96-107.